Biomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine, and Blood

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Molecular Diagnosis & Therapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF03256296PMID 18803429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

  2017cited by this paper
• Biomarkers of neurodegeneration

  2014cited by this paper
• P1–209: Comparison of auditory P300 responses in healthy elderly, people with mild cognitive impairment and people with Alzheimer's disease

  2013cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Diagnostic accuracy of Alzheimer’s disease: A clinicopathological study

  2009cited by this paper
• Diagnostic accuracy of alzheimer’s disease: A neuropathological study

  2009cited by this paper
• Clinical proteomics in neurodegenerative disorders

  2008cited by this paper
• Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease.

  2008cited by this paper
• Practical utility of urinary assay in the diagnosis of Alzheimer’s disease: AlzheimAlert™

  2008cited by this paper
• Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI

  2007cited by this paper
• Disease-modifying therapies for Alzheimer disease

  2007cited by this paper
• Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.

  2007cited by this paper
• Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease

  2007cited by this paper
• Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

  2007cited by this paper
• Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

  2007cited by this paper
• A Novel Panel of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Alzheimer’s Disease versus Normal Aging and Frontotemporal Dementia

  2007cited by this paper
• Biological Markers in Alzheimer's Disease

  2007cited by this paper
• Transcriptional profiling of Alzheimer blood mononuclear cells by microarray.

  2007cited by this paper
• A multi-center blinded prospective study of urine neural thread protein measurements in patients with suspected Alzheimer's disease.

  2007cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006cited by this paper
• Evaluation of DNA microarray results with quantitative gene expression platforms

  2006cited by this paper
• The future of genomic profiling of neurological diseases using blood.

  2006cited by this paper
• Biomarkers in the Diagnosis of Alzheimer’s Disease: Are We Ready?

  2006cited by this paper
• The Role of Biomarkers in Clinical Trials for Alzheimer Disease

  2006cited by this paper
• Evaluating the comparability of gene expression in blood and brain

  2006cited by this paper
• Proteome-based plasma biomarkers for Alzheimer's disease.

  2006cited by this paper
• Biological markers in Alzheimer's disease.

  2006cited by this paper
• Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies.

  2006cited by this paper
• The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

  2006cited by this paper
• Enzyme-Linked Immunosorbent Assay

  2006cited by this paper
• Gene expression profile analysis of lymphocytes from Alzheimer's patients

  2005cited by this paper
• Advances on biological markers in early diagnosis of Alzheimer disease.

  2005cited by this paper
• CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.

  2005cited by this paper
• Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers

  2005cited by this paper
• Lymphocytes as a neural probe: potential for studying psychiatric disorders.

  2004cited by this paper
• Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

  2004cited by this paper
• Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

  2004cited by this paper
• Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain

  2004cited by this paper
• Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

  2004cited by this paper
• Alzheimer's disease.

  2004cited by this paper
• Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases.

  2004cited by this paper
• Strategies for disease modification in Alzheimer's disease

  2004cited by this paper
• Core biological marker candidates of Alzheimer’s disease – perspectives for diagnosis, prediction of outcome and reflection of biological activity

  2004cited by this paper
• Alzheimer's disease: paired helical filament immunoreactivity in cerebrospinal fluid

  2004cited by this paper
• Biomarkers of Alzheimer disease in plasma

  2004cited by this paper
• Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

  2004cited by this paper
• Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

  2004cited by this paper
• CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.

  2003cited by this paper
• Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease.

  2003cited by this paper
• Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

  2003cited by this paper
• High cholesterol affects platelet APP processing in controls and in AD patients.

  2003cited by this paper
• Neuropathology of Cognitively Normal Elderly

  2003cited by this paper
• Decreased Cerebrospinal Fluid Acetylcholinesterase in Patients with Subcortical Ischemic Vascular Dementia

  2003cited by this paper
• Alzheimer disease in the US population: prevalence estimates using the 2000 census.

  2003cited by this paper
• Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk.

  2003cited by this paper
• CSF markers for Alzheimer's disease: Total tau, phospho-tau and Aβ42

  2003cited by this paper
• Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.

  2003cited by this paper
• Combination of serum markers related to several mechanisms in Alzheimer's disease.

  2003cited by this paper
• CSF tau protein and β‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population

  2003cited by this paper
• Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.

  2003cited by this paper
• A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease

  2003cited by this paper
• Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

  2003cited by this paper
• CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

  2003cited by this paper
• Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds

  2003cited by this paper
• CSF markers for incipient Alzheimer's disease.

  2003cited by this paper
• 17beta-estradiol reduces plasma Abeta40 for HRT-naïve postmenopausal women with Alzheimer disease: a preliminary study.

  2003cited by this paper
• Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk

  2003cited by this paper
• Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels

  2003cited by this paper
• 17β-Estradiol Reduces Plasma Aβ40 for HRT-Naïve Postmenopausal Women With Alzheimer Disease: A Preliminary Study

  2003cited by this paper
• Clinical biomarkers in drug discovery and development

  2003cited by this paper
• Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

  2002cited by this paper
• Amyloidosis and Alzheimer's disease.

  2002cited by this paper
• Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.

  2002cited by this paper
• CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

  2002cited by this paper
• Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.

  2002cited by this paper
• Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

  2002cited by this paper
• Research evaluation and prospective diagnosis of dementia with Lewy bodies.

  2002cited by this paper
• Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

  2002cited by this paper
• Inflammation and therapeutic vaccination in CNS diseases

  2002cited by this paper
• Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease.

  2002cited by this paper
• Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid.

  2002cited by this paper
• Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients.

  2002cited by this paper
• Tau and A&bgr;42 protein in CSF of patients with frontotemporal degeneration

  2002cited by this paper
• Relationships Among Cerebrospinal Fluid Biomarkers in Dementia of the Alzheimer Type

  2002cited by this paper
• Lipid peroxidation in aging brain and Alzheimer's disease.

  2002cited by this paper
• Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms

  2002cited by this paper
• Mitochondrial involvement in Parkinson's disease.

  2002cited by this paper
• Peripheral F2‐isoprostanes and F4‐neuroprostanes are not increased in Alzheimer's disease

  2002cited by this paper
• Biological Markers for Alzheimer's Disease

  2001cited by this paper
• Amyloid precursor protein in platelets

  2001cited by this paper
• Plasma levels of amyloid β proteins did not differ between subjects taking statins and those not taking statins

  2001cited by this paper
• Cerebrospinal Fluid Amyloid β1–42 Levels in the Mild Cognitive Impairment Stage of Alzheimer's Disease

  2001cited by this paper
• Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome

  2001cited by this paper
• The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer’s Disease, Reflecting a Common Pathophysiological Process

  2001cited by this paper
• Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

  2001cited by this paper
• Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease

  2001cited by this paper
• Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide.

  2001cited by this paper
• Both total and phosphorylated tau are increased in Alzheimer's disease

  2001cited by this paper
• Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231

  2001cited by this paper
• Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment.

  2001cited by this paper

• Frontotemporal dementia as a consequence of GRN mutations: from disease cause to models to therapies.

  2025cites this paper
• A New Optical Interferometric Biosensing System Enhanced with Nanoparticles for Alzheimer’s Disease in Serum

  2023cites this paper
• Amyloid –β pathology in Alzheimer’s disease: A nano delivery approach

  2023cites this paper
• Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimer’s disease

  2022cites this paper
• An ultrasensitive and selective PPY-fMWCNT nanocomposite electrical-transducer based Chemiresistive immunosensing platform for early detection of Alzheimer's

  2022cites this paper
• Requirement of brain interleukin33 for aquaporin4 expression in astrocytes and glymphatic drainage of abnormal tau

  2021cites this paper
• Zinc stable isotopes in urine as diagnostic for cancer of secretory organs.

  2021cites this paper
• Towards point-of-care diagnosis of Alzheimer's disease: Multi-analyte based portable chemiresistive platform for simultaneous detection of β-amyloid (1-40) and (1-42) in plasma.

  2021cites this paper
• Discovery of plasma protein biomarkers related to Alzheimers disease, sex and APOE genotype.

  2020cites this paper
• Traditional Chinese medicine for anti-Alzheimer’s disease: berberine and evodiamine from Evodia rutaecarpa

  2020cites this paper
• Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.

  2020cites this paper
• Current and Novel Strategies for Biomarkers Detection in Neurodegenerative Diseases: Future Graphene-Based Applications

  2018cites this paper
• The emerging roles of protein homeostasis‐governing pathways in Alzheimer's disease

  2018cites this paper
• Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.

  2017cites this paper
• DISEASE PROGRESSION AND TREATMENT STRATEGIES FOR THE MANAGEMENT OF ALZHEIMER’S DISEASE: AN OVERVIEW

  2017cites this paper
• Biomarkers in the Diagnosis and Prognosis of Alzheimer’s Disease

  2015cites this paper
• Alzheimer-associated urine neuronal thread protein level increases with age in a healthy Chinese population.

  2014cites this paper
• Prediction of Mild Cognitive Impairment that Evolves into Alzheimer's Disease Dementia within Two Years using a Gene Expression Signature in Blood: A Pilot Study

  2013cites this paper
• Novel tacrine-ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity.

  2013cites this paper
• Enfermedad de Alzheimer

  2012cites this paper
• Genomic and transcriptomic analyses distinguish classic Rett and Rett-like syndrome and reveals shared altered pathways.

  2011cites this paper
• The future of Alzheimer's disease: the next 10 years.

  2011cites this paper
• DNA methylation in repetitive elements and Alzheimer disease.

  2011cites this paper
• A Gene Expression Pattern in Blood for the Early Detection of Alzheimer's Disease

  2011cites this paper
• A Novel Blood Test for the Early Detection of Alzheimer's Disease

  2011cites this paper
• Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study

  2011cites this paper
• Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.

  2010cites this paper
• Current Therapies and New Strategies for the Management of Alzheimer’s Disease

  2010influential citation
• Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old

  2010cites this paper
• Die klinische Chemie – Herausforderung der Medizin für die analytische Chemie und die Nanowissenschaften

  2010cites this paper
• Clinical chemistry: challenges for analytical chemistry and the nanosciences from medicine.

  2009cites this paper